HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis.

Proc Natl Acad Sci U S A
Authors
Keywords
Abstract

Systemic juvenile idiopathic arthritis (sJIA) is an often severe, potentially life-threatening childhood inflammatory disease, the pathophysiology of which is poorly understood. To determine whether genetic variation within the MHC locus on chromosome 6 influences sJIA susceptibility, we performed an association study of 982 children with sJIA and 8,010 healthy control subjects from nine countries. Using meta-analysis of directly observed and imputed SNP genotypes and imputed classic HLA types, we identified the MHC locus as a bona fide susceptibility locus with effects on sJIA risk that transcended geographically defined strata. The strongest sJIA-associated SNP, rs151043342 [P = 2.8 × 10(-17), odds ratio (OR) 2.6 (2.1, 3.3)], was part of a cluster of 482 sJIA-associated SNPs that spanned a 400-kb region and included the class II HLA region. Conditional analysis controlling for the effect of rs151043342 found that rs12722051 independently influenced sJIA risk [P = 1.0 × 10(-5), OR 0.7 (0.6, 0.8)]. Meta-analysis of imputed classic HLA-type associations in six study populations of Western European ancestry revealed that HLA-DRB1*11 and its defining amino acid residue, glutamate 58, were strongly associated with sJIA [P = 2.7 × 10(-16), OR 2.3 (1.9, 2.8)], as was the HLA-DRB1*11-HLA-DQA1*05-HLA-DQB1*03 haplotype [6.4 × 10(-17), OR 2.3 (1.9, 2.9)]. By examining the MHC locus in the largest collection of sJIA patients assembled to date, this study solidifies the relationship between the class II HLA region and sJIA, implicating adaptive immune molecules in the pathogenesis of sJIA.

Year of Publication
2015
Journal
Proc Natl Acad Sci U S A
Volume
112
Issue
52
Pages
15970-5
Date Published
2015 Dec 29
ISSN
1091-6490
URL
DOI
10.1073/pnas.1520779112
PubMed ID
26598658
PubMed Central ID
PMC4702958
Links
Grant list
N1R01-AR062886 / AR / NIAMS NIH HHS / United States
RC1 AR058587 / AR / NIAMS NIH HHS / United States
Z01-HG200370 / HG / NHGRI NIH HHS / United States
Z01-AR041198 / AR / NIAMS NIH HHS / United States
R01-AR059049 / AR / NIAMS NIH HHS / United States
R01 AR060893 / AR / NIAMS NIH HHS / United States
20385 / Arthritis Research UK / United Kingdom
R01-DK076025 / DK / NIDDK NIH HHS / United States
R01 AR059049 / AR / NIAMS NIH HHS / United States
076113 / Wellcome Trust / United Kingdom
AG041718 / AG / NIA NIH HHS / United States
Intramural NIH HHS / United States
085475 / Wellcome Trust / United Kingdom
MR/M004600/1 / Medical Research Council / United Kingdom
AG030653 / AG / NIA NIH HHS / United States
T32 AR050942 / AR / NIAMS NIH HHS / United States
R01 DK076025 / DK / NIDDK NIH HHS / United States
UL1 TR001073 / TR / NCATS NIH HHS / United States
20542 / Arthritis Research UK / United Kingdom
P50 AG005133 / AG / NIA NIH HHS / United States
098051 / Wellcome Trust / United Kingdom
R01 AR062886 / AR / NIAMS NIH HHS / United States
R01-AR060893 / AR / NIAMS NIH HHS / United States
UL1 TR001425 / TR / NCATS NIH HHS / United States
U01-DK062420 / DK / NIDDK NIH HHS / United States
R01 AG030653 / AG / NIA NIH HHS / United States
R01 AG041718 / AG / NIA NIH HHS / United States
AG005133 / AG / NIA NIH HHS / United States
20386 / Arthritis Research UK / United Kingdom
P30 AR047363 / AR / NIAMS NIH HHS / United States
U01 DK062420 / DK / NIDDK NIH HHS / United States